» Articles » PMID: 11457826

Interleukin-1beta Induces Chronic Activation and De Novo Synthesis of Neutral Ceramidase in Renal Mesangial Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2001 Jul 18
PMID 11457826
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The lipid signaling molecule ceramide is formed by the action of acid and neutral sphingomyelinases and degraded by acid and neutral ceramidases. Short-term stimulation of mesangial cells with the pro-inflammatory cytokine interleukin-1beta (IL-1beta) leads to a rapid and transient increase in neutral sphingomyelinase activity (Kaszkin, M., Huwiler, A., Scholz, K., van den Bosch, H., and Pfeilschifter, J. (1998) FEBS Lett. 440, 163-166). In this study, we report on a second delayed peak of activation occurring after hours of IL-1beta treatment. This second phase of activation was first detectable after 2 h of treatment and steadily increased over the next 2 h, reaching maximal values after 4 h. In parallel, a pronounced increase in neutral ceramidase activity was observed, accounting for a constant or even decreased level of ceramide after long-term IL-1beta treatment, despite continuous sphingomyelinase activation. The increase in neutral ceramidase activity was due to expressional up-regulation, as detected by an increase in mRNA levels and enhanced de novo protein synthesis. The increase in neutral ceramidase protein levels and activity could be blocked dose- dependently by the p38 MAPK inhibitor SB 202190, whereas the classical MAPK pathway inhibitor U0126 and the protein kinase C inhibitor Ro 318220 were ineffective. Moreover, cotreatment of cells for 24 h with IL-1beta and SB 202190 led to an increase in ceramide formation. Interestingly, IL-1beta-stimulated neutral ceramidase activation was not reduced in mesangial cells isolated from mice deficient in MAPK-activated protein kinase-2, which is a downstream substrate of p38 MAPK, thus suggesting that the p38 MAPK-mediated induction of neutral ceramidase occurs independently of the MAPK-activated protein kinase-2 pathway. In summary, our results suggest a biphasic regulation of sphingomyelin hydrolysis in cytokine-treated mesangial cells with delayed de novo synthesis of neutral ceramidase counteracting sphingomyelinase activity and apoptosis. Neutral ceramidase may thus represent a novel cytoprotective enzyme for mesangial cells exposed to inflammatory stress conditions.

Citing Articles

Ceramides are fuel gauges on the drive to cardiometabolic disease.

Wilkerson J, Tatum S, Holland W, Summers S Physiol Rev. 2024; 104(3):1061-1119.

PMID: 38300524 PMC: 11381030. DOI: 10.1152/physrev.00008.2023.


Immunolocalization of Sphingolipid Catabolism Enzymes along the Nephron: Novel Early Urinary Biomarkers of Renal Damage.

Franco M, Cano-Martinez A, Ramos-Godinez M, Lopez-Marure R, Donis-Maturano L, Santamaria Sosa J Int J Mol Sci. 2023; 24(23).

PMID: 38068956 PMC: 10706607. DOI: 10.3390/ijms242316633.


Cross-Regulation of the Cellular Redox System, Oxygen, and Sphingolipid Signalling.

Huwiler A, Beck K, Pfeilschifter J Metabolites. 2023; 13(3).

PMID: 36984866 PMC: 10054022. DOI: 10.3390/metabo13030426.


Functions of neutral ceramidase in the Golgi apparatus.

Sakamoto W, Coant N, Canals D, Obeid L, Hannun Y J Lipid Res. 2018; 59(11):2116-2125.

PMID: 30154232 PMC: 6210901. DOI: 10.1194/jlr.M088187.


Neutral ceramidase-enriched exosomes prevent palmitic acid-induced insulin resistance in H4IIEC3 hepatocytes.

Zhu Q, Zhu R, Jin J FEBS Open Bio. 2016; 6(11):1078-1084.

PMID: 27833848 PMC: 5095145. DOI: 10.1002/2211-5463.12125.